S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Beam Therapeutics Inc.

BEAM · Healthcare · · USD
29.66 USD
+0.00 (0.68%)
● Updated 2026-09-07 19:37 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Mid-term (Position)

66
/ 100
Technical 100
Trend & RS 66
Momentum 64
Fundamental 22
Macro 64
Liquidity 31
ComponentScoreWeight
Technical 100.0 20%
Trend & RS 66.0 30%
Momentum 64.0 15%
Fundamental 22.2 10%
Macro 64.4 20%
Liquidity 31.1 5%

Trade Setup

Entry 29.66
Stop Loss 26.52 (10.6%)
Target 1 (1:1) 32.80 (+10.6%)
Target 2 (2:1) 35.94 (+21.2%)
ATR(14) 1.57 (5.3%)
Risk per Share 3.14
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 76.0 +1.04
Momentum 64.0 +0.56
Quality 34.5 -0.62
Composite 58.2

Quality Scores

Piotroski F-Score 2 /9 — Weak
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio N/A 22.0 Inline
P/B Ratio 2.8 4.0 Below

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
43.35%
Full Kelly
21.68%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 66/100. Estimated win rate 60%, avg win 9.0%, avg loss 3.7%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

4
Bullish Signals
0
Bearish Signals
54.25
RSI(14)
0.3689
MACD

Relative Strength (RS) WEAKENING

52
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↓ FALLING (-3.8% vs SPY 3M)
RS vs Sector UNDERPERFORMING (Healthcare)
RS New High No (43d since high)
Sector Outperformance -6.9% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
WEAKENING: Losing momentum — the stock was performing well but is now falling behind the market.

Technical Indicators

IndicatorValueSignal
Rsi 54.25 NEUTRAL
Macd 0.3689 BULLISH
Ma Cross 29.35 / 28.53 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.75x NORMAL

Key Levels

LevelPrice
52-Week High38.26
Bollinger Upper31.46
SMA(200)28.53
SMA(50)29.35
SMA(20)28.56
Current Price29.66
Bollinger Lower25.66
52-Week Low19.36
ATR(14)1.57

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

ACCUMULATION B Confidence
67%
Volume Dry-Up (Accumulation)
Acc: 2.0  |  Dist: 1.0  |  Markup: 0.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 0.83x Normal bar — no special VSA pattern
2026-09-01 No Demand 0.57x Low volume, narrow spread, weak close — no buying interest
2026-09-02 Normal 0.82x Normal bar — no special VSA pattern
2026-09-03 Normal 0.81x Normal bar — no special VSA pattern
2026-09-04 Normal 0.75x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 29.75 Above Kijun
Kijun-sen (26) 28.08 Base line
Senkou A 28.91 Leading span A
Senkou B 31.46 Leading span B
Cloud 28.91 – 31.46 Bearish (Red)
Price vs Cloud 29.66 Inside Cloud
Chikou Span 25.52 Bullish
Alignment Score 2/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH
BB: 25.66 – 31.46  |  KC: 26.37 – 30.75

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bullish RSI 4

Anchored VWAP

VWAP: 27.79 Anchor: 2025-09-05 (52w Low) ABOVE AVWAP +6.7%

Heikin-Ashi Trend

WEAKLY BULLISH Full data via /api/advanced/BEAM

Valuation

MetricValue
Market Cap3.06B
P/E (TTM)N/A
Forward P/EN/A
P/B2.78
EPS-0.69

Financial Health

MetricValue
Revenue Growth-94.2%
Profit Margin-55.4%
ROE-8.2%
Debt/Equity23.17
Current Ratio14.57
Dividend YieldN/A
Payout RatioN/A
Beta2.23

Trading Data

29.66
Open
29.66
Day High
29.66
Day Low
1.18M
Volume (0.6x avg)

Recent News (8)

Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb
Simply Wall St. · 2026-08-26
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Zacks · 2026-08-24
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Zacks · 2026-08-05
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 2026-08-04
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 2026-07-30
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Barrons.com · 2026-07-30
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
Motley Fool · 2026-07-20
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)
Insider Monkey · 2026-07-15

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —